Establishment Labs (NASDAQ:ESTA) Stock Price Down 7.1% – Here’s Why

Establishment Labs Holdings Inc. (NASDAQ:ESTA) shares dropped 7.1% during trading on Monday . The stock traded as low as $65.11 and last traded at $63.9750. Approximately 161,868 shares were traded during mid-day trading, a decline of 44% from the average daily volume of 289,139 shares. The stock had previously closed at $68.84.

Analysts Set New Price Targets

Several research analysts have issued reports on ESTA shares. JPMorgan Chase & Co. increased their price objective on Establishment Labs from $71.00 to $80.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 17th. Mizuho increased their price target on shares of Establishment Labs from $85.00 to $90.00 and gave the company an “outperform” rating in a report on Wednesday, December 17th. Needham & Company LLC boosted their price objective on shares of Establishment Labs from $70.00 to $84.00 and gave the stock a “buy” rating in a report on Wednesday, December 10th. Weiss Ratings restated a “sell (e+)” rating on shares of Establishment Labs in a research report on Monday, December 29th. Finally, Wall Street Zen raised shares of Establishment Labs from a “sell” rating to a “hold” rating in a report on Sunday, October 19th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $78.86.

Establishment Labs Stock Down 3.5%

The firm’s fifty day simple moving average is $67.10 and its 200-day simple moving average is $50.42. The company has a market cap of $1.93 billion, a PE ratio of -23.39 and a beta of 0.92. The company has a quick ratio of 2.10, a current ratio of 3.33 and a debt-to-equity ratio of 15.06.

Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.16. Establishment Labs had a negative net margin of 43.45% and a negative return on equity of 235.45%. The business had revenue of $53.78 million during the quarter, compared to analysts’ expectations of $52.28 million. During the same period last year, the company posted ($0.59) EPS. The company’s revenue was up 33.8% on a year-over-year basis. As a group, equities research analysts expect that Establishment Labs Holdings Inc. will post -2.41 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Establishment Labs by 20.1% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 57,215 shares of the company’s stock valued at $2,335,000 after buying an additional 9,557 shares during the period. Mudita Advisors LLP boosted its holdings in Establishment Labs by 15.6% in the first quarter. Mudita Advisors LLP now owns 479,359 shares of the company’s stock valued at $19,560,000 after acquiring an additional 64,859 shares during the last quarter. Guided Capital Wealth Management LLC boosted its holdings in Establishment Labs by 13.2% in the second quarter. Guided Capital Wealth Management LLC now owns 49,742 shares of the company’s stock valued at $2,124,000 after acquiring an additional 5,789 shares during the last quarter. Patriot Financial Group Insurance Agency LLC grew its position in Establishment Labs by 5.2% during the second quarter. Patriot Financial Group Insurance Agency LLC now owns 6,025 shares of the company’s stock valued at $257,000 after acquiring an additional 300 shares during the period. Finally, CWM LLC increased its stake in Establishment Labs by 45.9% during the second quarter. CWM LLC now owns 2,182 shares of the company’s stock worth $93,000 after acquiring an additional 686 shares during the last quarter. 72.91% of the stock is currently owned by hedge funds and other institutional investors.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.